Issue 4 - Jan 26, 2018
Issue 3 - Jan 19, 2018
  • Guest Editorial

    A unique drug for each patient: a paradigm shift in cancer therapy

    The recent FDA approvals of a cell/gene therapy for patients with advanced B cell malignancies provide a glimpse into a paradigm shift in the treatment of hematologic and solid cancers, the creation of a new drug unique to each cancer patient.

  • News Analysis

    As government shutdown looms, don’t lose sight of bigger battle over appropriations, sequestration

    As the rancor in Washington continues to escalate from bickering to a war on many fronts, the deadline approaches for the end of a continuing resolution that keeps the federal government open until Jan. 19.

  • In Brief

    • Allison, Bax, Doudna and Chang receive NAS prizes
    • Kathy Albain receives first Huizenga Family Endowed Chair at Loyola University Chicago
    • ACS CAN: Cancer patients should be exempt from possible Medicaid work requirements
    • ACCC’s 2017 survey: cost of treatment is top threat to cancer program growth
  • TCCL Logo

  • Clinical Roundup

    • Blood test for eight cancer types provides framework for early detection
    • Study shows screening population for select genes is a cost-effective solution
    • Polygenic hazard score predicts when men develop prostate cancer
    • Exelixis and Ipsen announce phase III trial results of Cabozantinib in advanced hepatocellular carcinoma
  • Drugs and Targets

    • Foundation Medicine and Pfizer form partnership to develop companion diagnostics
    • FDA approves addition of overall survival data to Kyprolis
    • Novartis granted FDA Priority Review for Kymriah for adults with r/r DLBCL
  • CTEP Protocols

    NCI CTEP-Approved Trials for January

    The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.

    For further information, contact the principal investigator listed.

Issue 2 - Jan 12, 2018